Combination of ursodeoxycholic acid and glucocorticoids upregulates the AE2 alternate promoter in human liver cells

Journal of Clinical Investigation

Volumn 118, Issue 2, 2008, Pages 695-709

  Arenas, Fabián ^a   Hervias, Isabel ^a   Úriz, Miriam ^a   Joplin, Ruth ^b   Prieto, Jesús ^a   Medina, Juan F ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

^b UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; HEPATOCYTE NUCLEAR FACTOR 1; ISOPROTEIN; MESSENGER RNA; PROTEIN P300; URSODEOXYCHOLIC ACID;

ARTICLE; CELL LINEAGE; CHROMATIN IMMUNOPRECIPITATION; GENE EXPRESSION; GENE SEQUENCE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL; MONOTHERAPY; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; PROMOTER REGION; UPREGULATION;

ANIMALS; ANION TRANSPORT PROTEINS; ANTIPORTERS; CELL LINE; CHOLAGOGUES AND CHOLERETICS; CHROMATIN IMMUNOPRECIPITATION; DEXAMETHASONE; DRUG THERAPY, COMBINATION; GENE EXPRESSION REGULATION; GLUCOCORTICOIDS; HEPATOCYTE NUCLEAR FACTOR 1-ALPHA; HEPATOCYTE NUCLEAR FACTOR 1-BETA; HEPATOCYTES; HUMANS; LIVER CIRRHOSIS, BILIARY; MICE; MUTATION; P300-CBP TRANSCRIPTION FACTORS; PROMOTER REGIONS (GENETICS); TRANSCRIPTION, GENETIC; UP-REGULATION; URSODEOXYCHOLIC ACID;

EID: 38849104576     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI33156     Document Type: Article

References (58)

1. Beuers, U. 2006. Drug insight: mechanisms and sites of action of ursodeoxycholic acid in cholestasis. Nat. Clin. Pract. Gastroenterol. Hepatol. 3:318-328.
2. Paumgartner, G., and Beuers, U. 2002. Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited. Hepatology. 36:525-531.
3. Lazaridis, K.N., Gores, G.J., and Lindor, K.D. 2001. Ursodeoxycholic acid 'mechanisms of action and clinical use in hepatobiliary disorders'. J. Hepatol. 35:134-146.
4. Poupon, R., et al. 1987. Is ursodeoxycholic acid an effective treatment for primary biliary cirrhosis? Lancet. 1:834-836.
5. Heathcote, E.J., et al. 1994. The Canadian Multicenter Double-blind Randomized Controlled Trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology. 19:1149-1156.
6. Lindor, K.D., et al. 1994. Ursodeoxycholic acid in the treatment of primary biliary cirrhosis. Gastroenterology. 106:1284-1290.
7. Angulo, P., et al. 1999. Long-term ursodeoxycholic acid delays histological progression in primary biliary cirrhosis. Hepatology. 29:644-647.
8. Corpechot, C., et al. 2005. The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis. Gastroenterology. 128:297-303.
9. Pares, A., Caballeria, L., and Rodes, J. 2006. Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic acid. Gastroenterology. 130:715-720.
10. Leuschner, M., et al. 1996. Ursodeoxycholic acid and prednisolone versus ursodeoxycholic acid and placebo in the treatment of early stages of primary biliary cirrhosis. J. Hepatol. 25:49-57.
11. Leuschner, M., et al. 1999. Oral budesonide and ursodeoxycholic acid for treatment of primary biliary cirrhosis: results of a prospective double-blind trial. Gastroenterology. 117:918-925.
12. Holtmeier, J., and Leuschner, U. 2001. Medical treatment of primary biliary cirrhosis and primary sclerosing cholangitis. Digestion. 64:137-150.
13. Angulo, P., et al. 2000. Oral budesonide in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid. Hepatology. 31:318-323.
14. Rautiainen, H., et al. 2005. Budesonide combined with UDCA to improve liver histology in primary biliary cirrhosis: a three-year randomized trial. Hepatology. 41:747-752.
15. Sola, S., Amaral, J.D., Aranha, M.M., Steer, C.J., and Rodrigues, C.M. 2006. Modulation of hepatocyte apoptosis: cross-talk between bile acids and nuclear steroid receptors. Curr. Med. Chem. 13:3039-3051.
16. Knyrim, K., Vakil, N., Pfab, R., and Classen, M. 1989. The effects of intraduodenal bile acid administration on biliary secretion of ionized calcium and carbonate in man. Hepatology. 10:134-142.
17. Perez Barriocanal, F., Marin, J.J., Dumont, M., and Erlinger, S. 1990. Influence of backward perfusion on ursodeoxycholate-induced choleresis in isolated in situ rat liver. J. Hepatol. 11:165-171.
18. Alpini, G., et al. 2002. Ursodeoxycholate and tauroursodeoxycholate inhibit cholangiocyte growth and secretion of BDL rats through activation of PKC alpha. Hepatology. 35:1041-1052.
19. Prieto, J., et al. 1999. Assessment of biliary bicarbonate secretion in humans by positron emission tomography. Gastroenterology. 117:167-172.
20. Medina, J.F., Martinez, A., Vazquez, J.J., and Prieto, J. 1997. Decreased anion exchanger 2 immunoreactivity in the liver of patients with primary biliary cirrhosis. Hepatology. 25:12-17.
21. Banales, J.M., et al. 2006. Bicarbonate-rich choleresis induced by secretin in normal rat is taurocholate-dependent and involves AE2 anion exchanger. Hepatology. 43:266-275.
22. Alper, S.L. 2006. Molecular physiology of SLC4 anion exchangers. Exp. Physiol. 91:153-161.
23. - transporters. Pflugers Arch. 447:495-509.
24. Medina, J.F., Lecanda, J., Acin, A., Ciesielczyk, P., and Prieto, J. 2000. Tissue-specific N-terminal isoforms from overlapping alternate promoters of the human AE2 anion exchanger gene. Biochem. Biophys. Res. Commun. 267:228-235.
25. Kurschat, C.E., et al. 2006. Alkaline-shifted pHo sensitivity of AE2c1-mediated anion exchange reveals novel regulatory determinants in the AE2 N-terminal cytoplasmic domain. J. Biol. Chem. 281:1885-1896.
26. Malumbres, R., et al. 2003. HNF1α upregulates the human AE2 anion exchanger gene (SLC4A2) from an alternate promoter. Biochem. Biophys. Res. Commun. 311:233-240.
27. Suh, D.S., and Rechler, M.M. 1997. Hepatocyte nuclear factor 1 and the glucocorticoid receptor synergistically activate transcription of the rat insulin-like growth factor binding protein-1 gene. Mol. Endocrinol. 11:1822-1831.
28. Lin, B., Morris, D.W., and Chou, J.Y. 1998. Hepatocyte nuclear factor 1α is an accessory factor required for activation of glucose-6-phosphatase gene transcription by glucocorticoids. DNA Cell Biol. 17:967-974.
29. Bristeau, A., Catherin, A.M., Weiss, M.C., and Faust, D.M. 2001. Hormone response of rodent phenylalanine hydroxylase requires HNF1 and the glucocorticoid receptor. Biochem. Biophys. Res. Commun. 287:852-858.
30. Soutoglou, E., Papafotiou, G., Katrakili, N., and Talianidis, I. 2000. Transcriptional activation by hepatocyte nuclear factor-1 requires synergism between multiple coactivator proteins. J. Biol. Chem. 275:12515-12520.
31. Soutoglou, E., et al. 2001. Transcription factor-dependent regulation of CBP and P/CAF histone acetyltransferase activity. EMBO J. 20:1984-1992.
32. Ban, N., et al. 2002. Hepatocyte nuclear factor-1α recruits the transcriptional co-activator p300 on the GLUT2 gene promoter. Diabetes. 51:1409-1418.
33. Dohda, T., et al. 2004. Transcriptional coactivators CBP and p300 cooperatively enhance HNF1α-mediated expression of the albumin gene in hepatocytes. J. Biochem. (Tokyo) 136:313-319.
34. Barbacci, E., et al. 2004. HNF1β/TCF2 mutations impair transactivation potential through altered co-regulator recruitment. Hum. Mol. Genet. 13:3139-3149.
35. Almlof, T., Wallberg, A.E., Gustafsson, J.A., and Wright, A.P. 1998. Role of important hydrophobic amino acids in the interaction between the glucocorticoid receptor tau 1-core activation domain and target factors. Biochemistry. 37:9586-9594.
36. Miura, T., et al. 2001. Functional modulation of the glucocorticoid receptor and suppression of NF-κB-dependent transcription by ursodeoxycholic acid. J. Biol. Chem. 276:47371-47378.
37. Sola, S., et al. 2005. Nuclear translocation of UDCA by the glucocorticoid receptor is required to reduce TGF-β1-induced apoptosis in rat hepatocytes. Hepatology. 42:925-934.
38. Weitzel, C., et al. 2005. Ursodeoxycholic acid induced activation of the glucocorticoid receptor in primary rat hepatocytes. Eur. J. Gastroenterol. Hepatol. 17:169-177.
39. +-taurocholate cotransporting polypeptide gene is activated by glucocorticoid receptor and peroxisome proliferator-activated receptor-γ coactivator-1α, and suppressed by bile acids via a small heterodimer partner-dependent mechanism. Mol. Endocrinol. 20:65-79.
40. Truss, M., and Beato, M. 1993. Steroid hormone receptors: interaction with deoxyribonucleic acid and transcription factors. Endocr. Rev. 14:459-479.
41. Prieto, J., Qian, C., Garcia, N., Diez, J., and Medina, J.F. 1993. Abnormal expression of anion exchanger genes in primary biliary cirrhosis. Gastroenterology. 105:572-578.
42. Corpechot, C., et al. 2001. Apolipoprotein E polymorphism, a marker of disease severity in primary biliary cirrhosis? J. Hepatol. 35:324-328.
43. Beato, M. 1989. Gene regulation by steroid hormones. Cell. 56:335-344.
44. Schoneveld, O.J., Gaemers, I.C., and Lamers, W.H. 2004. Mechanisms of glucocorticoid signalling. Biochim. Biophys. Acta. 1680:114-128.
45. Witchel, S.F., and DeFranco, D.B. 2006. Mechanisms of disease: regulation of glucocorticoid and receptor levels - impact on the metabolic syndrome. Nat. Clin. Pract. Endocrinol. Metab. 2:621-631.
46. Yuan, L.W., and Giordano, A. 2002. Acetyltransferase machinery conserved in p300/CBP-family proteins. Oncogene. 21:2253-2260.
47. Collingwood, T.N., Urnov, F.D., and Wolffe, A.P. 1999. Nuclear receptors: coactivators, corepressors and chromatin remodeling in the control of transcription. J. Mol. Endocrinol. 23:255-275.
48. Vo, N., and Goodman, R.H. 2001. CREB-binding protein and p300 in transcriptional regulation. J. Biol. Chem. 276:13505-13508.
49. Black, J.C., Choi, J.E., Lombardo, S.R., and Carey, M. 2006. A mechanism for coordinating chromatin modification and preinitiation complex assembly. Mol. Cell. 23:809-818.
50. Guermah, M., Palhan, V.B., Tackett, A.J., Chait, B.T., and Roeder, R.G. 2006. Synergistic functions of SII and p300 in productive activator-dependent transcription of chromatin templates. Cell. 125:275-286.
51. Akare, S., et al. 2006. Ursodeoxycholic acid modulates histone acetylation and induces differentiation and senescence. Int. J. Cancer. 119:2958-2969.
52. Li, Q., Su, A., Chen, J., Lefebvre, Y.A., and Hache, R.J. 2002. Attenuation of glucocorticoid signaling through targeted degradation of p300 via the 26S proteasome pathway. Mol. Endocrinol. 16:2819-2827.
53. Alvaro, D., et al. 2002. Corticosteroids modulate the secretory processes of the rat intrahepatic biliary epithelium. Gastroenterology. 122:1058-1069.
54. Joplin, R., et al. 1992. Human intrahepatic biliary epithelial cells proliferate in vitro in response to human hepatocyte growth factor. J. Clin. Invest. 90:1284-1289.
55. Courtois, G., Baumhueter, S., and Crabtree, G.R. 1988. Purified hepatocyte nuclear factor 1 interacts with a family of hepatocyte-specific promoters. Proc. Natl. Acad. Sci. U. S. A. 85:7937-7941.
56. Liu, F., Song, Y., and Liu, D. 1999. Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA. Gene Ther. 6:1258-1266.
57. Zhang, G., Budker, V., and Wolff, J.A. 1999. High levels of foreign gene expression in hepatocytes after tail vein injections of naked plasmid DNA. Hum. Gene Ther. 10:1735-1737.
58. Johnson, K.D., and Bresnick, E.H. 2002. Dissecting long-range transcriptional mechanisms by chromatin immunoprecipitation. Methods. 26:27-36.